[Thrombolysis in acute myocardial infarct]

Area of Science:

• Cardiology
• Pharmacology
• Emergency Medicine

Background:

• Acute myocardial infarction (AMI) is primarily caused by coronary artery thrombus.
• Thrombolysis has been the standard treatment for AMI since the 1980s, supported by extensive research.
• Early studies like ISIS-2 and GISSI demonstrated thrombolysis's mortality-reducing benefits.

Purpose of the Study:

• To review the evolution and efficacy of thrombolytic therapies for AMI.
• To compare different thrombolytic agents and regimens, including streptokinase, TPA, and anistreplase.
• To analyze the benefits and risks, particularly bleeding complications, associated with thrombolysis and adjunctive therapies.

Main Methods:

• Review of major randomized clinical trials (ISIS-2, GISSI, ISIS-3, GISSI-2, GUSTO).
• Comparison of mortality reduction and adverse events across different thrombolytic strategies.
• Evaluation of adjunctive treatments like aspirin and heparin in conjunction with thrombolysis.

Main Results:

• Streptokinase and TPA showed comparable efficacy in some studies, while anistreplase was less effective.
• The GUSTO study indicated a slight survival advantage with accelerated TPA regimens over streptokinase, particularly in American centers.
• Increased bleeding complications, including cerebral hemorrhages, are associated with thrombolysis, especially when combined with aspirin and heparin, though benefits often outweigh risks.

Conclusions:

• Thrombolysis remains a cornerstone of AMI treatment, with ongoing refinements in drug choice and administration.
• Optimizing the use of adjunctive heparin is crucial, with timing varying between streptokinase and TPA.
• Balancing the life-saving potential of thrombolysis against bleeding risks is essential for patient management.